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of	CKD	 is	 retained,	 an	enhanced	 classification	 framework	 is	 proposed.	 This	 is	 to	 allow	 for	
better	 prognostication	 and	 management	 decisions.	 The	 2012	 guidelines
3







































the	 New	 Zealand	 renal	 replacement	 population	 at	 874	 per	 million
9






















renal	 replacement	 therapy	 or	 an	 active	 conservative	 care	 pathway.	 Renal	 replacement	
therapy	encompasses	both	dialysis	and	renal	transplantation.	Transplantation	(either	living	
or	deceased	donor)	remains	the	best	treatment	for	ESKD,	but	is	often	deferred	by	necessity	
due	 to	 shortage	 of	 available	 organs.	 Dialysis	 provides	 an	 artificial	 replacement	 of	 kidney	
filtration	 although	 lacks	 the	 tubular	 and	 endocrine	 functions	 of	 the	 kidney.	 General	
indications	to	commence	dialysis	are	often	a	combination	of	GFR	<	10	ml/min,	development	




along	 an	 electrochemical	 concentration	 gradient
12
.	 The	 primary	 goal	 of	 both	 haemo-	 and	
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increased	 risk	 of	 SCD	 in	 ESKD;	 interstitial	 fibrosis	 due	 to	 chronic	 uraemia,	 microvascular	
disease	 or	 endothelial	 dysfunction,	 calcium/phosphate	 deposition	 and	 significant	 left	
ventricular	 hypertrophy	 have	 been	 implicated
22
.	 Additionally,	 an	 increased	 electrical	
instability	 may	 be	 seen	 due	 to	 fluid	 shifts,	 autonomic	 imbalance,	 chronic	 inflammation,	
acid/base	 disturbances,	 and	 electrolyte	 abnormalities
22
.	 The	 true	 risk	 of	 ventricular	
arrhythmias	is	likely	due	to	a	combination	of	these	many	interacting	factors.	
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1.2 The	Nervous	System	
	
The	 nervous	 system	 coordinates	 voluntary	 and	 involuntary	 actions	 and	 transmits	 signals	
between	different	parts	of	the	body.	It	consists	of	two	main	parts,	the	central	nervous	system	
and	 the	 peripheral	 nervous	 system.	 The	 central	 nervous	 system	 comprises	 the	 brain	 and	
spinal	cord.	The	peripheral	nervous	system	represents	all	tissues	distal	to	the	spinal	cord.	It	
includes	 motor	 neurons	 mediating	 voluntary	 movement;	 the	 autonomic	 nervous	 system,	
comprising	the	sympathetic	and	parasympathetic	nervous	system	and	regulating	involuntary	






and	 the	 maintenance	 of	 homeostasis	 of	 the	 internal	 environment.	 It	 regulates	 visceral	
function	 primarily	 through	 its	 interaction	 with	 the	 endocrine	 system	 and	 via	 autonomic	
reflexes.	The	general	anatomy	of	the	efferent	systems	is	illustrated	over	the	page.	
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Figure	3:	The	Efferent	Systems	of	the	Sympathetic	and	Parasympathetic	Divisions	of	the	Autonomic	Nervous	System23	
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and	 hypothalamus,	 have	 important	 connections	 with	 the	 autonomic	 nervous	 system	 and	
participate	in	the	integrated	regulation	of	visceral	function	and	homeostasis25.	Most	viscera	
and	 target	 organs	 of	 the	 autonomic	 nervous	 system	 have	 dual	 innervation	 from	 the	
sympathetic	 and	 parasympathetic	 nervous	 systems.	 Each	 system	 typically	 produces	
antagonistic	 effects.	 As	 such,	 a	 balance	 of	 activity	 between	 the	 sympathetic	 and	
parasympathetic	nervous	systems	helps	to	regulate	visceral	and	homeostatic	mechanisms.	 	






























Some	 pre-ganglionic	 fibres	 do	 not	 synapse	 in	 the	 paravertebral	 ganglia	 but	 instead	 pass	
through	the	ganglia	without	synapsing	and	form	splanchnic	nerves.	These	nerves	innervate	
three	pre-vertebral	ganglia,	the	coeliac	and	superior	and	inferior	mesenteric	ganglia.	Second-





nerves	directly	 innervate	the	chromaffin	cells.	This	 facilitates	secretion	of	 the	sympathetic	

















receptor	 is	 identified	by	differing	 responsiveness	 to	 sympathomimetic	 amines.	 The	 alpha-
adrenoreceptor	is	associated	with	most	of	the	excitatory	functions	(e.g.	vasoconstriction	and	
stimulation	of	the	uterus,	ureter	and	dilator	pupillae)	and	one	important	inhibitory	function	









in	 increased	 synthesis	 of	 cyclic	 adenosine	monophosphate	 (AMP)	 whereas	 α-2	 receptors	
produce	 a	 respective	 reduction29.	 Alpha-2	 receptors	 located	 primarily	 on	 the	 presynaptic	
sympathetic	 nerve	 terminals	 inhibit	 norepinephrine	 release	 and	 thus	 have	 an	 inhibitory	




The	 α-1	 receptors	 are	 responsible	 for	 relaxation	 of	 gastrointestinal	 smooth	 muscle,	

























also	 decreases	 renal	 blood	 flow	whilst	 renal	 denervation	 leads	 to	 a	 respective	 increase33.	
These	data	 supported	 the	 conclusion	 that	 sympathetic	 nerve	 fibres	 enter	 the	 renal	 hilum	
along	the	main	renal	artery	and	innervate	the	renal	vasculature34.	
	
The	 advent	 of	 electron	 microscopy	 allowed	 Müller	 et	 al	 to	 demonstrate	 that	 intrarenal	
sympathetic	 nerve	 fibres	 also	 make	 direct	 contact	 with	 tubular	 epithelial	 basolateral	
membranes	 throughout	 the	 entire	 nephron35.	 This	 innervation	 is	 functional;	 increased	
sympathetic	nerve	activity	 leads	 to	 increases	 in	 renin	secretion	rate,	 renal	 tubular	sodium	
reabsorption	with	anti-natriuresis	 as	well	 as	 renal	 vasoconstriction36.	 Stimulation	of	 fibres	
causes	 a	 graded	 response	 dependent	 on	 the	 intensity	 of	 the	 sympathetic	 signal36.	 At	 the	
lowest	level,	there	is	increased	renin	secretion	mediated	by	β-1	adrenoreceptors	located	on	
the	renin-containing	juxtaglomerular	granular	cells37.	At	a	slightly	higher	level	of	sympathetic	
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activity	there	is	an	additional	anti-natriuresis.	This	is	mediated	by	α-1b	receptors	located	on	
the	basolateral	membrane	of	 renal	 tubular	 epithelial	 cells	 in	 the	proximal	 tubule,	 loop	of	
Henle,	distal	tubule	and	the	collecting	duct37.	At	the	highest	level	of	renal	sympathetic	nerve	
activity,	there	is	also	a	decrease	in	both	renal	blood	flow	and	glomerular	filtration	rate	(GFR).	
The	 renal	 vasoconstriction	 is	mediated	by	α-1a	 receptors	 located	on	 the	 vascular	 smooth	
muscle	cells	of	the	intrarenal	resistance	vasculature37.	
	







α-1a	 adrenoreceptors	 in	 the	 intrarenal	 resistance	 vasculature37.	 Subsequent	 activation	 of	
phospholipase	 C	 (PLC)	 hydrolyses	 phosphatidylinositol	 4,5	 bisphosphate	 (PIP2)	 to	 inositol	
triphosphate	(IP3)	and	diacylglycerol	(DAG)37.	In	turn,	DAG	can	activate	protein	kinase	C	(PKC),	





Na+/H+	 exchanger	 (NHE)-1,	 NHE-3	 and	 sodium	 bicarbonate	 cotransporter	 (NBC)	 in	 the	
proximal	tubule;	Na-K-2Cl	cotransporter	(NKCC2)	in	the	thick	ascending	limb	of	Henle’s	loop;	
and	 Na-K-ATPase	 throughout	 the	 nephron37.	 In	 renal	 tubular	 epithelial	 cells,	 α-1b	
adrenoreceptor	 stimulation	 activates	 multiple	 signalling	 pathways.	 Activation	 of	 Gq/11	
engages	 PKC-dependent	 pathways,	 which	 increases	 the	 activity	 of	 basolateral	 NHE-1.	
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Activation	of	a	PKC-independent	mitogen	activated	protein	kinase	(MAPK)	pathway	increases	
the	activity	of	apical	NHE-3.	Activation	of	the	PLC-PIP2-IP3	pathway	raises	intracellular	calcium	




Gs,	 which	 increases	 adenylate	 cyclase	 and	 cyclic	 adenosine	 monophosphate	 (cAMP)	
concentration	leading	to	protein	kinase	A	(PKA)	activation	and	exocytic	renin	release37.	





















































































































































































In	 addition,	 suboptimal	 blood	 pressure	 is	 the	 number	 one	 attributable	 risk	 for	 death	
throughout	the	world61.	
	
Hypertension	 is	 unsurprisingly	 common	 in	New	Zealand,	 affecting	 at	 least	 1	 in	 6	 adults62.	



















the	 development	 and	 maintenance	 of	 hypertension	 through	 stimulation	 of	 the	 heart,	
peripheral	 vasculature	 and	 kidneys,	 causing	 increased	 cardiac	 output,	 increased	 vascular	
resistance,	and	fluid	retention65.	
	










muscle	 cell	 proliferation	 and	 vascular	 remodeling64.	 Norepinephrine	 spillover	 studies	 also	




The	 mechanisms	 of	 increased	 sympathetic	 nervous	 system	 activity	 in	 hypertension	 are	
complex	and	involve	alterations	in	baroreflex	and	chemoreflex	pathways	at	both	peripheral	
and	 central	 levels.	 Arterial	 baroreceptors	 reset	 to	 a	 higher	 pressure	 in	 hypertensive	
patients68.	There	is	also	central	resetting	of	the	aortic	baroreflex,	resulting	in	suppression	of	
sympathetic	 inhibition	after	 activation	of	 the	aortic	baroreceptor	nerves69.	 The	baroreflex	
resetting	is	at	least	partly	mediated	by	a	central	action	of	angiotensin	II70.	Angiotensin	II’s	role	
is	 complex;	 it	 also	 facilitates	 the	 pre-synaptic	 release	 of	 norepinephrine,	 inhibits	 synaptic	




Alongside	 angiotensin	 II,	 there	 are	 additional	 small-molecule	 mediators	 that	 suppress	
baroreceptor	 activity	 and	 contribute	 to	 exaggerated	 sympathetic	 drive.	 These	 include	
reactive	 oxygen	 species72	 and	 endothelin73.	 Finally,	 there	 is	 evidence	 of	 exaggerated	
chemoreflex	function,	leading	to	markedly	enhanced	sympathetic	activation	in	response	to	
stimuli	such	as	apnoea	and	hypoxia74.	This	is	clinically	relevant	in	the	setting	of	obstructive	
sleep	 apnoea	 where	 exaggerated	 sympathetic	 nerve	 activity	 is	 demonstrable	 alongside	
hypertension75.	
	
Chronic	 sympathetic	 stimulation	 induces	 vascular	 remodelling	 and	 left	 ventricular	
hypertrophy	 by	 the	 direct	 and	 indirect	 actions	 of	 norepinephrine.	 There	 is	 activation	 of	
norepinephrine’s	 own	 receptors,	 as	 well	 as	 release	 of	 various	 trophic	 factors,	 including	
transforming	 growth	 factor-β	 (TGF-β),	 insulin-like	 growth	 factor	 1,	 and	 fibroblast	 growth	
factors66.	 A	 positive	 correlation	 exists	 between	 circulating	 norepinephrine	 levels,	 left	
ventricular	 mass,	 and	 reduced	 radial	 artery	 compliance	 (an	 index	 of	 vascular	
hypertrophy)76,77.	Thus,	 sympathetic	mechanisms	contribute	 to	 the	development	of	 target	
organ	damage,	as	well	as	to	the	pathogenesis	of	hypertension.	
	 	





Thoracolumbar	 sympathectomy	 was	 introduced	 in	 the	 1930s	 for	 patients	 with	 severe	
hypertension.	The	aim	was	to	recreate	the	vasodilatory	effect	seen	after	experimental	nerve	
section	to	reduce	peripheral	vascular	resistance	and	hence	blood	pressure.	The	procedure	
involved	 two	 stages	 carried	 out	 10	 days	 apart.	 A	 retropleural,	 retroperitoneal,	
transdiaphragmatic	approach	was	employed	through	the	beds	of	the	12th	or	the	11th	and	12th	
ribs.	The	sympathetic	trunks	were	removed	from	the	eighth	or	ninth	dorsal	vertebrae	through	
to	 the	 first	 or	 second	 lumbar	 vertebra	 inclusive,	 and	 the	 great	 splanchnic	 nerves	 were	
removed	 from	 the	 coeliac	 ganglion	 to	 the	 mid-thoracic	 level.	 The	 procedure	 improved	
mortality78	(notably	more	so	than	best	medical	therapy	at	the	time78)	although	the	associated	






Ganglion	 blockers	 represented	 the	 first	 pharmacological	 alternative.	 They	 compete	 with	
acetylcholine	 for	 sympathetic	 ganglionic	 cholinoceptive	 sites	 and	 prevent	 post-synaptic	
depolarization79.	 They	 have	 no	 effect	 on	 catecholamine	 neurotransmission	 at	 the	 post-
ganglionic	terminal	or	on	peripheral	arterioles.	Increased	peripheral	pooling	as	a	consequence	
of	venous	dilatation	leads	to	decreased	venous	return	to	the	heart	and	a	fall	in	cardiac	output;	
renal	 blood	 flow,	GFR	and	 cerebral	 blood	 flow	are	 frequently	 diminished;	 skeletal	muscle	
blood	flow	is	unaltered,	coronary	flow	is	variable80.	Side	effects	from	non-specific	ganglionic	
blockade	 are	 unfortunately	 numerous.	 Parasympathetic	 blockade	 leads	 to	 dry	 mucous	
membranes	 and	 skin	 and	 paralysis	 of	 accommodation;	 postural	 hypotension	 is	 common;	




developed.	 Unreliable	 absorption	 from	 the	 gastrointestinal	 (GI)	 tract,	 exacerbated	 by	
treatment-induced	 impaired	 GI	motility,	meant	 oral	 therapy	was	 unsatisfactory	 however.	
Subsequently,	mecamylamine	was	developed;	as	a	 long-acting	 tertiary	amine	 it	was	more	
reliably	absorbed	from	the	GI	tract,	although	was	variably	excreted	in	the	urine83.	
	
Rauwolfia	 alkaloids	 were	 the	 next	 sympatholytics	 to	 market.	 They	 inhibit	 chemical	
neurotransmission	 at	 post-ganglionic	 sympathetic	 nerve	 fibres,	with	 resultant	 decrease	 in	
peripheral	vascular	resistance.	In	addition,	they	affect	sympathetic	discharge	from	vasomotor	
centres	 and	 the	 hypothalamus84.	 Side	 effects	 result	 from	 unopposed	 parasympathetic	
activity:	bradycardia,	excess	salivation,	nausea	and	diarrhoea,	nasal	congestion,	gastric	acid	
secretion	and	peptic	ulcer	 formation.	 The	 central	 sympatholytic	 effects	may	also	 result	 in	




Page 31 of 108	
Methyldopa	acts	as	a	competitive	inhibitor	in	the	biosynthetic	pathway	of	catecholamines,	
reducing	 synthesis	 of	 dopamine	 and	 norepinephrine	 at	 adrenergic	 post-ganglionic	 nerve	
endings.	 It	also	forms	the	false	neurotransmitter	alpha-methyl-norepinephrine	that	fails	to	




Guanethidine	 also	 acts	 by	 disruption	 of	 the	 adrenergic	 post-ganglionic	 nerve	 terminals,	
thereby	 decreasing	 arteriolar	 vasoconstriction.	 It	 prevents	 the	 release	 of	 norepinephrine	
from	the	post-ganglionic	nerve	terminals	and	depleting	the	stores	of	norepinephrine	at	these	
terminals81.	The	clinical	effects	of	guanethidine	result	from	the	sympatholytic	effects	on	the	
heart	 and	manifest	 as	 postural	 hypotension,	 often	 a	 treatment-limiting	 side	 effect.	Other	





Monoamine	 oxidase	 inhibitors	 (MAOIs)	 act	 primarily	 on	 the	 sympathetic	 post-ganglionic	
nerve	 terminals.	 Inhibition	 of	 norepinephrine	 synthesis	 occurs	 due	 to	 accumulation	 of	
norepinephrine	 and	 false	 neurotransmitters	 result	 in	 attenuated	 signalling81.	 The	 effects	
develop	after	three	to	four	weeks	and	GFR	is	slightly	reduced.	Several	adverse	reactions	have	
been	 reported;	 hepatocellular	 necrosis,	 blood	 dyscrasias	 and	 optic	 atrophy.	 Symptomatic	
postural	 hypotension	 is	 a	 frequent	 and	 troublesome	 problem.	 Tyramine	 containing	 foods	
such	 as	 aged	 cheese	 can	 also	 cause	 serious	 reactions	 so	 for	 the	most	 part	MAOIs	 use	 is	
restricted81.	
	




predecessor	 that	 specifically	 blocked	 the	 positive	 inotropic	 and	 chronotropic	 effects	 of	
adrenergic	 stimuli88.	 It	 heralded	 one	 of	 the	 most	 important	 advances	 in	 cardiovascular	
pharmacotherapy	 with	 scores	 of	 variants	 developed.	 Beta-blockers	 became	 mainline	
treatment	 in	 hypertension,	 arrhythmia,	 thyrotoxicosis,	 hypertrophic	 cardiomyopathy,	
migraine	and	glaucoma89.	Subsequent	variants	with	selectivity	for	beta-1	(cardio-stimulation,	
lipolytic)	 and	 beta-2	 (broncho-	 and	 vasodilatation)	 were	 developed90,	 others	 with	 alpha-





effects	 occur	 in	 5-10%	 of	 people	 with	 dizziness,	 fatigue,	 paraesthesia,	 depression	 and	
gastrointestinal	 disturbances	 commonly	 reported.	 More	 serious	 reactions	 including	
pulmonary	 oedema,	 hypotension,	 and	 heart	 block	 are	 fortunately	 rare94.	 Treatment	with	
beta-adrenergic	 blockers	 affects	 diurnal	 sodium	 excretion;	more	 is	 excreted	 at	 night	 and	
during	 the	 early	morning	hours88.	 	 Traditional	 agents	 can	 also	 lead	 to	 a	 loss	 of	 glycaemic	
control	 and	dyslipidaemia.	 In	 contrast,	 vasodilating	beta-blockers	 (nebivolol,	 labetalol	 and	






















as	 is	 renal	blood	flow	and	GFR	unless	the	hypotensive	effect	 is	profound81.	Unfortunately,	




veratrum	 alkaloids,	 even	 for	 the	management	 of	 hypertensive	 crises	 where	 they	 initially	
found	favour.	
	
Alpha-antagonists	 lower	 blood	 pressure	 by	 selectively	 blocking	 post-synaptic	 α1-
adrenoreceptors,	which	antagonizes	catecholamine-induced	constriction	of	the	arterial	and	
venous	vascular	beds101.	 The	 first	 generation	of	alpha-receptor	antagonists,	phentolamine	
and	phenoxybenzamine,	were	of	 the	nonselective	 variety;	numerous	 therapy-limiting	 side	
effects	 resulted	 from	 their	 additional	 pre-synaptic	 blockade	 (orthostatic	 hypertension,	
tachycardia,	dizziness,	drowsiness,	syncope,	nausea	and	nasal	congestion).	In	1976,	prazosin	
was	first	approved	for	use	in	the	United	States.	It	had	the	advantage	of	not	interfering	with	
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1.3.5.3 Endovascular	Renal	Denervation	
	
In	 the	 last	 decade,	 a	 novel	 procedure	 of	 endovascular	 renal	 denervation	 has	 been	
developed104.	Unlike	the	traditional	invasive	surgical	approach,	this	involves	a	percutaneous,	
catheter-based	 method	 whereby	 radiofrequency	 waves	 are	 applied	 to	 the	 endothelial	
surfaces	of	both	renal	arteries.	The	treatment	causes	controlled	burns	through	to	the	tunica	
adventitia,	 the	 location	 of	 the	 afferent	 pre-ganglionic,	 and	 efferent	 post-ganglionic	 renal	
nervous	supply.	Nerve	tissue	is	particularly	sensitive	to	thermal	injury.	Post-ablation	histology	
from	 pre-clinical	 swine	 studies	 reveals	 a	 pattern	 of	 nerve	 fibrosis,	 replacement	 of	 nerve	
fascicles	with	fibrous	connective	tissue,	and	thickening	of	the	epineurium	and	perineurium105.	




The	 first	 large	 clinical	 trial	 of	 endovascular	 renal	 denervation	 involved	a	 case	 series	of	 45	
patients	with	resistant	hypertension104.	This	was	defined	as	a	blood	pressure	greater	 than	
140/90	 despite	 three	 anti-hypertensive	 medications	 (including	 a	 diuretic)	 at	 maximal	
tolerated	dosage.	A	significant	office-based	blood	pressure	reduction	at	one-month	follow-
up	of	 14/10	mmHg	was	 followed	by	 a	 sustained	 response	 at	 12	months	of	 27/17	mmHg.	
Procedural	 complications	 were	 limited	 to	 one	 renal	 arterial	 dissection	 due	 to	 catheter	




based	 therapy	 in	 addition	 to	 conventional	 anti-hypertensive	 medications	 versus	 anti-
hypertensive	medications	 only.	 There	was	 a	 significant	 difference	 in	 blood	 pressure	 from	
baseline	 to	 six	month	 follow-up	 of	 33/11	mmHg	 between	 treatment	 groups106.	 Following	
patient	 cross-over	 at	 six	 months,	 further	 analysis	 at	 12	 months107	 suggested	 the	





Although	 not	 universal108,	 the	 suggestion	 that	 sympathetic	 hyperactivity	 associated	 with	










Chronic	 kidney	 disease	 is	 characterised	 by	marked	 activation	 of	 the	 sympathetic	 nervous	
system,	 as	 evidenced	 by	 increased	 levels	 of	 circulating	 norepinephrine	 and	 an	 elevated	
number	 of	 sympathetic	 neural	 bursts	 recorded	 in	 the	 peroneal	 nerve	 via	
microneurography111,112.	The	residual	kidneys	are	critically	involved	in	the	pathogenesis	of	the	


























Parallel	 activation	 of	 the	 renin-angiotensin	 system	 also	 occurs	 following	 ischaemic	 renal	
injury113,	 resulting	 in	 increased	 peripheral	 and	 central	 sympathetic	 activity.	 Angiotensin	 II	
facilitates	 the	 pre-synaptic	 release	 of	 norepinephrine,	 inhibits	 its	 synaptic	 reuptake	 and	
enhances	tissue	response71.	It	also	stimulates	the	sympathetic	ganglia	and	adrenal	medulla	
effecting	an	increase	in	circulating	epinephrine	and	norepinephrine71.	Lastly,	Angiotensin	II	
directly	 stimulates	 brainstem	 sympathetic	 signalling71.	 Aldosterone,	 acting	 via	
mineralocorticoid	receptors,	also	increases	sympathetic	nerve	activity	by	up-regulating	the	
brain	 renin-angiotensin	 system	 components	 and	 induction	 of	 oxidative	 stress	 in	 the	
hypothalamus122.	 Consequentially	 there	 is	 up-regulation	 not	 only	 of	 peripheral,	 but	 also	
central	sympathetic	activity	following	ischaemic	renal	injury.		
	
Although	 renal	 ischaemia	 is	 key,	 it	 does	 not	 represent	 the	 complete	 pathophysiological	
picture.	 Autonomic	 dysfunction	 is	 frequently	 observed	 in	 patients	with	 significant	 chronic	
kidney	 disease123.	 This	 is	 accompanied	 by	 many	 cardiovascular	 disturbances	 including	
dysfunction	of	 the	baroreflex	 arc124	 and	hyporesponsiveness	 of	 adrenergic	 receptors.	 It	 is	
thought	that	afferent	baroreflex	arc	dysfunction	(exacerbated	by	the	stiff	vessels	induced	by	
vascular	hypertrophy	and	calcification125)	leads	to	enhanced	sympathetic	outflow,	elevated	
plasma	 norepinephrine	 levels126	 and	 resultant	 down-regulation	 of	 adrenoreceptors127.	 A	
coexistent	 defect	 in	 coupling	 between	 the	 beta-adrenoreceptor	 and	 the	 effector	 enzyme	
adenylyl	cyclase128	and	reduced	density	and	binding	affinity	of	alpha	receptors127,129	has	also	
been	demonstrated.	Baroreceptor	and	adrenoreceptor	dysfunction	leaves	patients	with	an	




Uraemia	 cannot	 solely	 be	 blamed	 for	 the	 sympathetic	 hyperactivity	 in	 ESKD	 patients,	 as	
activity	 is	 similarly	 increased	 in	 patients	 who	 have	 undergone	 renal	 transplantation132.	
Accumulation	 of	 asymmetric	 dimethyl-l-arginine	with	 inhibition	 of	 endothelial	 nitric	 oxide	
synthase	and	hence	less	nitric	oxide	production	is	therefore	postulated	as	a	contributory	risk	
factor133.	 Neuronal	 nitric	 oxide	 is	 a	major	 component	 of	 the	 signal	 transduction	 pathway	
involved	in	the	tonic	restraint	of	central	sympathetic	outflow134.		
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1.4.2 Clinical	Significance	
	
Sympathetic	nerve	activity	 is	 inversely	correlated	with	estimated	glomerular	 filtration	rate	
(eGFR),	implicating	it	as	a	causal	agent	in	the	progressive	decline	in	kidney	function	seen	in	
hypertensive	 CKD	 patients111.	 Furthermore,	 sympatholytic	 drug	 treatment	 attenuates	
albumin	 excretion	 in	 rats135	 and	 in	 patients	 with	 diabetic	 nephropathy136.	 Sympatholytic	
treatment	 has	 also	 been	 shown	 to	 prevent	 glomerulosclerosis	 in	 experimental	






of	 sudden	 cardiac	 death	 in	 CKD	 and	 ESKD	 patients.	 Heart-rate	 variability	 (a	 marker	 of	
autonomic	 dysfunction)	 predicts	 ESKD-	 and	 CKD-related	 hospitalisation140	 as	 well	 as	
haemodialysis	 patient	 mortality141.	 Plasma	 norepinephrine	 predicts	 survival	 and	 incident	
cardiovascular	events	in	patients	with	ESKD142.	Lastly,	MSNA	associates	with	the	composite	
of	all-cause	mortality	and	nonfatal	cardiovascular	events	in	CKD	patients143.	The	mechanism	
for	 this	 relationship	 may	 well	 relate	 in	 part	 to	 left	 ventricular	 hypertrophy	 (LVH)	 and	
arrhythmogenesis144.	LVH	is	an	important,	 independent	determinant	of	survival	 in	patients	
receiving	therapy	for	ESKD145.	Sympathetic	activity	in	CKD146	and	ESKD147	patients	correlates	
with	 left	 ventricular	 mass	 despite	 antihypertensive	 treatment.	 Endovascular	 renal	
denervation	 appears	 to	 reduce	 left	 ventricular	 mass	 and	 improves	 systolic	 and	 diastolic	
function148,149	 although	 there	 have	 been	 no	 studies	 with	 these	 outcomes	 in	 an	 ESKD	
population	to	date.	
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1.5 Endovascular	Renal	Denervation	in	CKD	
	
Overall	 there	 are	 scant	 data	 concerning	 endovascular	 renal	 denervation	 in	 the	 CKD	 and	
dialysis	populations.	Hering	et	al150	performed	bilateral	renal	denervation	in	15	patients	with	
resistant	 hypertension	 and	CKD	 stage	3	 -	 4.	Mean	 reduction	 in	 office	blood	pressure	was	
33/19	mmHg	at	12	months,	night-time	ambulatory	blood	pressure	 significantly	decreased	





mmHg).	Ambulatory	blood	pressure	also	 fell	 substantially	 (19/7	mmHg)	and	 there	was	an	
improvement	seen	in	both	microalbuminuria	and	glomerular	filtration	rate.	This	is	in	keeping	




Similar	 procedures	 have	 been	 undertaken	 in	 ESKD	 patients.	 Although	 somewhat	 more	
technically	 challenging	 due	 to	 the	 smaller	 renal	 arteries	 induced	 by	 atrophic	 kidneys,	
procedures	have	been	on	the	whole	successful,	efficacious	and	safe153–155.	One	case	even	had	










Outside	 the	benefits	of	 improved	blood	pressure	 control	 and	 the	potential	 effects	on	 left	
ventricular	mass	and	function,	it	appears	renal	denervation	may	also	improve	central	arterial	





events,	 renal	 denervation	 has	 great	 promise	 in	 reducing	 the	 incidence	 of	 sudden	 cardiac	
death	in	dialysis	patients.	
	 	




to	be	advantageous	 for	 renal	pain	 control.	Autosomal	dominant	polycystic	 kidney	disease	
(ADPKD)	can	be	characterised	by	chronic	and	often	severe	abdominal,	flank,	or	back	pain.	The	










cardiovascular	 disease	 prevalence164.	 Obstructive	 sleep	 apnoea	 is	 also	 characterized	 by	
















sympathetic	nervous	 system	with	 the	 resultant	overactivity	 inducing	 insulin	 resistance	 via	
regional	 haemodynamic	 and	 possibly	 more	 direct	 cellular	 effects172.	 Although	 there	 is	 a	
demonstrably	 bidirectional	 experimental	 relationship,	 observational	 data	 suggest	
sympathetic	activation	may	in	fact	be	the	initial	trigger173.	Despite	these	encouraging	data,	it	




urinary	 albumin	 excretion	 following	 denervation,	 again	 without	 deleterious	 effects	 on	
glomerular	filtration	rate.	Their	study	was	run	in	parallel	to	the	Symplicity	trials	so	studied	a	
resistant	 hypertensive	 population	 with	 normal	 (eGFR	 ≥	 45)	 renal	 function.	 As	 such,	 an	
extrapolation	of	data	is	needed	but	as	markers	of	glomerular	hyperfiltration,	clear	relevance	
to	the	CKD	and	particularly	the	diabetic	nephropathy	population	is	apparent.	 	
Page 39 of 108	
1.5.2 Unanswered	Questions	
Endovascular	renal	denervation	is	a	rapidly	moving	field	of	research.	Technological	advances	
have	 already	 yielded	 device	 progression.	 Multi-electrode	 baskets	 have	 been	 designed	 to	
reduce	procedural	time	and	increase	procedural	efficacy175.	Radiofrequency	ablation	is	also	
not	the	only	option	now,	brachytherapy176,	chemical	denervation177,178,	cryoablation179	and	






cost-effectiveness183.	 	One	would	 remind	 readers	of	 the	analogy	with	 renal	angioplasty	 to	






is	 so	 far	 lacking.	 Case	 reports	 have	 demonstrated	 late	 renal	 artery	 stenosis	 can	 occur188	
although	with	what	 frequency	 is	yet	 to	be	established.	Advanced	 imaging	 techniques	also	
suggest	the	sparse	pre-clinical	studies	do	not	tell	the	complete	picture	regarding	the	effects	
of	ablation	on	the	renal	arteries.	Demonstrable	intimal	damage	with	intraluminal	thrombosis	
has	 been	 seen	 via	 optical	 coherence	 tomography	 post-procedure189.	 Dual	 anti-platelet	
therapy	for	between	three	and	six	months	has	consequently	been	proposed189	with	the	risk	
of	resultant	renal	ischaemia	and	micro-embolism	unknown.	










The	 effect	 of	 possible	 sympathetic	 re-innervation	 remains	 unclear.	 Studies	 of	 renal	
transplantation	 suggest	 axonal	 regeneration	 of	 sympathetic	 nerves	 occurs	 as	 early	 as	 the	
fourth	week	post-surgical	denervation192,	although	the	precise	functional	significance	of	this	











A	 trial	 of	 535	 patients	 in	 88	 centres,	 Symplicity	 HTN-3	 was	 prospective,	 single-blind,	
randomized	and,	 for	 the	 first	 time	with	 this	 technology,	 sham-controlled196.	 Patients	with	
severe	 resistant	 hypertension	 were	 randomly	 assigned	 in	 a	 2:1	 ratio	 to	 undergo	 renal	
denervation	or	a	sham	procedure.	The	mean	(±SD)	change	in	office	systolic	blood	pressure	at	
6	months	was	−14.13±23.93	mm	Hg	in	the	denervation	group	as	compared	with	−11.74±25.94	



















hypertension.	 It	may	also	yield	benefit	as	a	 tolerable	 sympatholytic	and	confer	advantage	
over	and	above	its	blood	pressure	lowering	effect.	Sympathetic	hyperactivity	is	linked	both	to	
chronic	kidney	disease	progression	and	associated	cardiovascular	comorbidity.	Applying	renal	
denervation	 to	 a	 CKD	 population	 may	 slow	 the	 inexorable	 progression	 towards	 renal	
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Individual	 patient	 measures	 at	 each	 time-point	 are	 presented	 in	 Table	 2.	 At	 baseline	 six	
patients	 had	 all	 measures	 assessed.	 The	 two	 diabetic	 patients	 had	 unsuccessful	 MSNA	
measurement,	 therefore	 they	were	 not	 reassessed	 in	 follow-up.	 Another	 patient	was	 not	
assessed	with	BCM	therefore	this	was	not	reassessed	in	follow-up.	At	1M	eight	patients	were	
fully	assessed	with	their	repeated	baseline	measures.	One	patient	temporarily	withdrew	from	
the	 study	 due	 to	 a	myocardial	 infarction,	 but	 returned	 to	 the	 study	 at	 3M.	 At	 3M	 seven	
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Table	2:	Measurements	Completed	for	the	Individual	Patients	Across	the	Study	
Patient	 Baseline	 1M	 3M	 12M	



























All	assessments	completed†.	 All	assessments	completed*†.	 All	assessments	completed†.	 Did	not	consent	to	MSNA	and	
blood	sampling.	All	other	
assessments	completed.	
	 All	assessments	completed.	 All	assessments	completed*.	 All	assessments	completed.	 All	assessments	completed†γ.	
	 All	assessments	completed.	 All	assessments	completed*.	 All	assessments	completed.	 All	assessments	completed.	
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3.1 Renal	Denervation	Procedure	
All	nine	patients	had	a	technically	successful	RDN.	A	total	of	143	ablation	sites	out	of	144	were	
completed	 to	 60	 s	 in	 this	 cohort,	 with	 142	 (eight	 in	 all	 but	 two	 vessels)	 performed	with	
acceptable	 temperature	 rises	 and	 impedances.	 During	 all	 procedures,	 the	 catheter	 and	
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3.2 Safety	
One	 patient	 sustained	 a	 severe	 pseudoaneurysm	 post-procedure	 that	 needed	 surgical	
management.	 One	 week	 post-procedure,	 six	 of	 nine	 had	 palpable	 femoral	 haematomas	
despite	the	application	of	Angio-Seal™.	One	patient	suffered	a	myocardial	infarction	four	days	
post-RDN	 and	 another	 died	 in	 the	 period	 between	 3M	 and	 12M	 from	 dialysis-related	
complications.	
	 	











At	 baseline	 LV	 mass	 in	 eight	 out	 of	 nine	 patients	 met	 the	 American	 Society	 of	




Anti-hypertensive	 therapy	 was	 kept	 constant	 after	 RDN,	 unless	 change	 was	 medically	
indicated	(Table	4).	Following	RDN,	mean	ambulatory	(24-hour	period)	BP	demonstrated	a	
gradual	and	evolving	reduction	which	became	significant	at	12M,	with	systolic	and	diastolic	


















































Page 68 of 108	
Table	3:	Change	in	Inferior	Vena	Caval	Parameters	
	





















	 17.00	 8.00	 8.20	 0.53	 11.00	 6.00	 5.25	 0.46	 15.00	 5.00	 7.40	 0.67	
	 20.00	 13.00	 12.85	 0.35	 22.00	 16.00	 13.81	 0.27	 19.00	 11.00	 11.99	 0.42	
	 23.00	 9.00	 10.61	 0.61	 15.00	 6.00	 7.11	 0.60	 9.00	 5.00	 4.17	 0.44	
	 24.00	 22.70	 12.75	 0.05	 17.00	 8.00	 9.34	 0.53	 	 	 	 	
	 14.00	 6.00	 7.82	 0.57	 9.00	 4.00	 5.13	 0.56	 11.00	 7.00	 6.47	 0.36	
	 20.00	 6.00	 11.57	 0.70	 19.00	 14.00	 10.95	 0.26	 18.00	 11.00	 10.27	 0.39	
	 25.00	 14.00	 12.66	 0.44	 21.00	 7.00	 10.19	 0.67	 21.00	 12.00	 10.11	 0.43	
	 18.00	 9.00	 10.18	 0.50	 16.00	 9.00	 9.02	 0.44	 10.00	 4.00	 5.61	 0.60	
	 30.00	 23.00	 16.04	 0.23	 	 	 	 	 27.00	 25.00	 15.07	 0.07	
	 	 	 	 	 	 	 	 	 	 	 	 	
Mean	 21.22	 12.30	 11.41	 0.44	 16.25	 8.75	 8.85	 0.47	 16.25	 10.00	 8.89	 0.42	
Standard	
Deviation	
4.82	 6.57	 2.56	 0.20	 4.56	 4.17	 2.95	 0.15	 6.21	 6.82	 3.63	 0.18	
	 	 	 	 	 	 	 	 	 	 	 	 	
Change	from	
Baseline	
	 	 	 	 -4.97	 -3.55	 -2.56	 0.03	 -4.97	 -2.30	 -2.52	 -0.02	
Paired	T-test		
(to	baseline)	
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Table	4:	Prescribed	Anti-Hypertensive	Therapy	
Patient	 Baseline	 1M	 3M	 12M	
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